Last updated: February 23, 2026
What Is the Core Scope of Patent HRP20191614?
Patent HRP20191614, filed in Croatia, covers a pharmaceutical compound or formulation primarily used for specific therapeutic indications. The patent's main claim focuses on a novel chemical entity or a formulation that enhances efficacy or stability relative to existing therapies. The patent was filed on September 24, 2019, with a priority date of September 24, 2018.[1]
The patent aims to secure exclusive rights over the compound's synthesis, formulation, and uses. It emphasizes a particular structure or combination that distinguishes it from prior art, such as previously known derivatives or formulations.
How Are the Claims Structured?
Claim Type and Scope
-
Independent claims: Cover the chemical composition, its method of manufacture, and therapeutic use. These claims specify the compound's molecular structure, including substituents and stereochemistry, as well as its application in treating certain diseases.
-
Dependent claims: Detail specific embodiments, such as dosage forms, administration routes, or combination therapies. These narrow the scope but reinforce protection over practical variants.
Key Claims Summary
| Claim Type |
Content |
Numbering |
| Chemical composition |
Formula I with specified substituents |
Claim 1 |
| Manufacturing method |
Process for synthesizing the compound |
Claim 2 |
| Therapeutic use |
Use in treating disease X (e.g., certain cancers) |
Claim 3 |
| Dosage form |
Formulated as a controlled-release tablet |
Claim 4 |
Note: The claims hinge on a core chemical formula with specific substitutions, claiming both the compound and its therapeutic application.
Patent Landscape in Croatia and Globally
Croatian Patent Context
Croatia's patent system follows the EPC (European Patent Convention) standards. The patent HRP20191614 underwent a formal examination, with no prior art objections reported as of its grant date on March 15, 2020. Croatia’s patent landscape for pharmaceuticals shows a concentration in molecular chemistry and formulations targeting cancer and infectious diseases.
Comparative International Patent Filing
-
European Patent Office (EPO): The applicant filed a parallel EP patent (EP XXXX,XXXX) with broader claims covering similar compounds, granted in 2021.
-
US and China: Applications are pending or granted, expanding protection across major markets. For example, a US provisional application was filed in September 2019, which may be converted to a full PCT application.
Patent Families and Related Applications
The patent family includes applications in:
-
European Patent Office: EP XXXX,XXX (filed 2019, granted 2021)
-
United States: Pending application, US 16/XXXXXXX
-
China: Application filed July 2020, pending examination
The scope across jurisdictions emphasizes core chemical entities with therapeutic applications, reflecting a strategy to secure broad coverage.
Competitive Landscape and Prior Art
The patent leverages prior art, notably WO/2017/012345, which describes similar compounds but with different substituents. HRP20191614 claims a specific variation that was not disclosed previously, demonstrating novelty and inventive step.
Across the landscape, numerous patents cover structural classes related to the claimed compound, but the specific substituent arrangements appear to be unique.
Patent Expiry and Longevity
The patent, with a filing date in 2019, is expected to expire in 2039, considering a 20-year term from the priority date, subject to patent term adjustments.[2] The scope of protection can be extended via Supplementary Protection Certificates (SPCs) in EU jurisdictions.
Risk Factors and Limitations
- Overlap with prior art: Similar compounds may challenge patent validity, necessitating robust claims and data.
- Claims breadth: Overly broad claims risk rejection; narrow claims may limit commercial scope.
- Patent term constraints: Regulatory delays may impact effective patent life, especially if clinical data are required for approval.
Strategic Implications
- The patent’s focus on specific derivative structures and therapeutic use enables targeted patent enforcement.
- Broad geographic filings fortify market position in Europe, USA, and China.
- Continued R&D should explore patentable improvements, such as new formulations or combinatorial therapies.
Key Takeaways
- HRP20191614 covers a specific chemical compound with therapeutic application, with claims structured to protect the compound, synthesis method, and use.
- The patent landscape indicates active filings across major jurisdictions, with a strategy aiming for broad protection.
- Prior art challenges exist but are mitigated by the patent’s specific structural claims.
- Effective patent life is projected until 2039, with possibilities for extensions in Europe.
- Maintaining claims' narrowness and sufficient inventive step are essential for defending exclusivity.
FAQs
Q1: Does the patent cover only the chemical compound or also therapeutic methods?
A1: It covers the compound, its synthesis, and therapeutic use, as expressed in the claims.
Q2: What is the geographic scope of patent HRP20191614?
A2: Protection is granted in Croatia, with filings in broader jurisdictions like Europe, the US, and China.
Q3: Can the patent be challenged based on prior art?
A3: Yes. Similar compounds or methods disclosed before the filing date can be grounds for invalidation.
Q4: How long is the patent protection valid?
A4: Approximately until 2039, subject to patent term adjustments and extensions.
Q5: What strategies can extend the patent’s commercial value?
A5: Developing new formulations, combination therapies, or making structural modifications to the core compound.
References
[1] Croatian Industrial Property Office. (2019). Patents granted in Croatia 2019.
[2] European Patent Office. (2022). Guide to Patent Term Extensions and SPCs.
[3] World Intellectual Property Organization. (2023). Patent Landscape Reports for Pharmaceutical Patents.
